People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Crossbow Therapeutics, Inc. | — | Biotechnology | Series B | $67.8M | $128.2M | 2025 |
Dmitri Wiederschain at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dmitri Wiederschain on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Foley | 1 | 12 |
| Briggs Morrison | 1 | 8 |
| Alexandra Cantley | 1 | 8 |
| Alon Lazarus | 1 | 7 |
| Sakae Asanuma | 1 | 6 |
| Alexander Nolte | 1 | 1 |
| Charles Baum | 1 | 1 |
| Irena Melnikova | 1 | 1 |
| Geraldine Paulus | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.